These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 7648765)

  • 21. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
    Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
    Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
    Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
    J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
    Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
    J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.
    Andersson T; Cederberg C; Edvardsson G; Heggelund A; Lundborg P
    Clin Pharmacol Ther; 1990 Jan; 47(1):79-85. PubMed ID: 2104790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
    Wang H; Nie YQ; Dai SJ; She QZ; Li YY
    Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):777-80. PubMed ID: 14636465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
    Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
    Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
    Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
    Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
    Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation.
    Yasumori T; Li QH; Yamazoe Y; Ueda M; Tsuzuki T; Kato R
    Pharmacogenetics; 1994 Dec; 4(6):323-31. PubMed ID: 7704038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study.
    Gram LF; Guentert TW; Grange S; Vistisen K; Brøsen K
    Clin Pharmacol Ther; 1995 Jun; 57(6):670-7. PubMed ID: 7781267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of inhibition of H+, K(+)-ATPase by sodium 2-[[4-(3- methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810).
    Nochi S; Yokoyama Y; Narukawa M; Ebine K; Murahashi M; Kawakami Y; Asakawa N; Sato T
    Chem Pharm Bull (Tokyo); 1996 Mar; 44(3):552-8. PubMed ID: 8882453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism.
    Kortunay S; Basci NE; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
    Eur J Clin Pharmacol; 1997; 53(3-4):261-4. PubMed ID: 9476042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.
    Chiba K; Kobayashi K; Manabe K; Tani M; Kamataki T; Ishizaki T
    J Pharmacol Exp Ther; 1993 Jul; 266(1):52-9. PubMed ID: 8331574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interethnic difference in omeprazole's inhibition of diazepam metabolism.
    Caraco Y; Tateishi T; Wood AJ
    Clin Pharmacol Ther; 1995 Jul; 58(1):62-72. PubMed ID: 7628184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.